Sana Biotechnology Inc at JPMorgan Healthcare Conference Transcript
Welcome everyone to the 42nd Annual JPMorgan Healthcare Conference. My name is Tessa Romero, and I'm one of the senior biotechnology analysts here at JPMorgan. Our next presenting company is Sana and presenting on behalf of the company, we have CEO, Steve Harr. Steve?
All right. Well, thank you, Tessa, and thank you, JPMorgan, for having us. Appreciate everybody in the audience who as I'm sure everybody recognizes will make a few forward-looking statements. So please do refer to our 10-Q. We spent a bunch of time running our risk factors for 2024 I think really promises to be an exciting and potentially translate, hopefully, transformative year for the company.
We spent a lot of 2023 preparing ourselves for a bunch of clinical data. And we at this time last year, we had no programs in clinical testing. Today, we have four across seven indications. We'll treat something like 40 to 60 patients in clinical studies this year, we'll have data available from every one of them.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |